Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.55 |
| ▸ | MAP2K2 | P36507 | 10/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24558566 | 0.90 | MAP2K2 (0.44) | MAP2K1MAP2K2NPC1MAPTNFKB1 | |
| SCHEMBL24558816 | 0.86 | MAP2K1 (0.51) | MAP2K1MAP2K2 | |
| SCHEMBL23852169 | 0.83 | MAP2K2 (0.57) | MAP2K1MAP2K2RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30827541 | 0.83 | MAP2K2 (0.57) | MAP2K1MAP2K2RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24558579 | 0.82 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL24558518 | 0.81 | MAP2K2 (0.54) | MAP2K1MAP2K2NPC1MAPTNFKB1 | |
| SCHEMBL24558708 | 0.80 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL24558537 | 0.79 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL24558699 | 0.79 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL26047543 | 0.78 | MAP2K1 (0.41) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, NAT1, BRAF | MAP2K1 455/4885MAP2K2 282/4885NPC1 2617/4885 |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885NPC1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.